LACTOLOGY FOUNDATION

Drugs in ATC class A02X (“Other drugs for acid‑related disorders”) are a heterogeneous small group used for prevention or treatment of acid‑related diseases but currently have no registered representatives in Bulgaria, and their lactation safety varies according to individual physicochemical and pharmacokinetic properties. Because of their diverse structures and mechanisms, each medicine requires separate evaluation, but most agents used today either have minimal systemic absorption or low transfer into breast milk and can often be used without interrupting breastfeeding when clinically justified.file+5

Place in ATC system

ATC group A02 comprises drugs for acid‑related disorders, including antacids (A02A), drugs for peptic ulcer and reflux disease (A02B), and a residual subgroup A02X for other agents that do not fit preceding categories. A02X is defined as “other drugs for acid‑related disorders” and typically includes preparations with gastroprotective effects or mucosal actions distinct from classic antacids, H2‑blockers, or proton‑pump inhibitors.wikipedia+2

General pharmacology in A02X

Medicines classed in A02X act primarily on the gastrointestinal mucosa to protect against acid‑induced injury, reduce ulcer risk, or aid mucosal healing, often via cytoprotective or prostaglandin‑mediated mechanisms. Representative examples in this therapeutic area include sucralfate, an aluminum‑sucrose sulfate complex that forms a protective barrier on ulcerated mucosa, and misoprostol, a prostaglandin E1 analogue that increases mucus and bicarbonate secretion and reduces gastric acid output while also having uterotonic effects.drugbank+1

Toxicological profile in adults

Toxicity within A02X is heterogeneous because compounds come from different chemical classes with distinct systemic effects and adverse‑reaction spectra. Sucralfate is minimally absorbed from the gastrointestinal tract, so systemic toxicity is usually low; adverse effects are predominantly gastrointestinal (constipation, bezoar formation in predisposed patients), although aluminum accumulation can be relevant in renal impairment. Misoprostol, in contrast, is systemically active, and its main toxicological concerns relate to dose‑dependent diarrhea, abdominal cramping, and its potent uterotonic and abortifacient properties, which can cause uterine rupture or severe bleeding in pregnant women.prescriberpoint+4

Pregnancy safety considerations

Because of minimal absorption, sucralfate is considered relatively safe in pregnancy and is often recommended as a first‑line option for gastroesophageal reflux or peptic ulcer symptoms when drug therapy is required. Misoprostol is contraindicated for routine ulcer prophylaxis in pregnant women because exposure can induce abortion, congenital anomalies, preterm birth, or uterine rupture, and its use in pregnancy is restricted to carefully supervised obstetric indications where the uterotonic effect is deliberately sought.droracle+3

Lactation risk determinants

For A02X medicines, lactation risk depends mainly on molecular weight, lipid solubility, oral bioavailability in the infant, and the plasma:milk ratio, which together determine how much drug or active metabolite reaches breast milk and how much can be absorbed by the breastfed child. Highly lipophilic and low‑molecular‑weight compounds with good oral bioavailability are more likely to concentrate in milk and pose a theoretical toxicological risk, whereas large, poorly absorbed molecules with low lipid solubility usually appear in milk at negligible or clinically irrelevant levels.breastfeeding-and-medication+2

Lactation categories (conceptual framework)

Within this project, lactation safety can be conceptualized using four toxicological lactation categories based on milk transfer and potential for adverse effects in the breastfed infant. Category I includes drugs or metabolites that either do not enter human milk or are non‑toxic at transferred amounts; Category II covers drugs that do appear in milk, but with low plasma:milk ratios or instability in the infant’s gastric environment, so that clinically important toxicity is not expected. Category III encompasses agents that generate milk concentrations comparable to or higher than maternal plasma and may cause infant toxicity, warranting temporary interruption of breastfeeding during maternal treatment, while Category IV includes highly toxic agents and/or those with high milk transfer for which breastfeeding is incompatible and a safer therapeutic alternative should be sought.file

Sucralfate during lactation

Sucralfate has a very low degree of systemic absorption, and available evidence indicates that transfer into human milk is minimal, with most authorities regarding it as acceptable during breastfeeding without the need for special precautions. On this basis, sucralfate can reasonably be classified in a low‑risk lactation category (analogous to Category I–II in the above scheme), and clinically significant adverse effects in breastfed infants are not expected when it is used at standard doses in otherwise healthy mothers.ncbi.nlm.nih+2

Misoprostol during lactation

Pharmacokinetic studies show that misoprostol acid appears in breast milk at low concentrations that decline rapidly, typically falling below 1 pg/mL within about five hours after dosing. Expert sources, including LactMed and national formularies, conclude that these low levels are unlikely to harm breastfed infants; breastfeeding can usually continue without interruption, although some authors suggest, as a precaution, spacing nursing by several hours after maternal dosing to further minimize exposure and monitoring the infant for transient diarrhea.ncbi.nlm.nih+2

Bulgarian market context

According to the referenced local toxicology‑lactology web resource, there are currently no registered medicinal products in Bulgaria that are formally classified within the ATC subgroup A02X, so this monograph provides a framework description rather than product‑specific local guidance. As new A02X agents become available on the Bulgarian market, each will need an individual toxicological and lactation‑focused assessment using the same determinants and category system outlined above.atcddd.fhi+2

Practical clinical considerations

When selecting an A02X agent for a breastfeeding woman, clinicians should prioritize drugs with minimal systemic absorption, low lipid solubility, and reassuring human lactation data, while also considering maternal renal function and overall comorbidity profile. For systemically active drugs such as misoprostol, prescribers must weigh the maternal benefit (e.g., ulcer prevention in high‑risk NSAID users or obstetric indications) against potential infant exposure and may individualize strategies such as timing of doses relative to feeds or temporary milk expression and discard if high doses are required.pmc.ncbi.nlm.nih+4